Industry News

• NIH study finds that coffee drinkers have lower risk of death  caffeinated or decaffeinated — had a lower risk of death overall than others who did not drink coffee, according a study by researchers from the NCI and AARP. The results of the study were published in the New England Journal of Medicine.
  May 17, 2012  
• World's first approved stem cell drug receives clearance from Health Canada  Osiris announced it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease in children. The decision marks the world's first regulatory approval of a manufactured stem cell product.
  May 17, 2012  
• Neurocrine Biosciences announces Urocortin 2 phase II study results   Neurocrine announced efficacy and safety results from a Phase II trial of urocortin 2 in patients with acute decompensated heart failure. The study was conducted over a two year period. Infusion of urocortin 2 was generally well tolerated and there were no treatment-related serious adverse events.
  May 17, 2012  
• Accelrys announces purchase of cloud-based HEOS drug discovery information technology  Accelrys announced the purchas of Web-based Hit Explorer Operating System from SCYNEXIS. The HEOS purchase is the final phase of an agreement that began in 2011, which enabled Accelrys to market and sell HEOS as a key offering within Accelrys' market-leading Cheminformatics Suite of applications.
  May 17, 2012  
• FDA approves generic versions of blood thinner Plavix  The FDA approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries.
  May 17, 2012  
• Saks Fifth Avenue raises $17,000 for TGen biomedical research  Saks Fifth Avenue raised more than $1.1 million in charitable contributions nationwide through its month-long February Charity Program, including $17,000 for TGen. TGen was one of 196 organizations nationwide to benefit from the drive.
  May 17, 2012  
• The Crohn's and Colitis Foundation of Canada and Vertex announce research collaboration  Vertex and the Crohn's and Colitis Foundation of Canada announced a new collaboration to fund novel research aimed at identifying the underlying disease mechanisms and drivers of inflammatory bowel disease, specifically Crohn's disease and ulcerative colitis.
  May 17, 2012  
• Positive phase 2 clinical data with Tivantinib in hepatocellular carcinoma presented  ArQule and Daiichi Sankyo announced Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma. Data demonstrated a statistically significant improvement in time-to-progression with significant improvements in progression-free survival.
  May 17, 2012  
• Agilent to acquire Dako for $2.2 billion  Agilent and EQT, the Sweden-based private equity group, announced an agreement to acquire Dako, the Denmark-based cancer diagnostic company for $2.2 billion. Dako's products are sold in more than 100 countries, and in 2010 its annual revenue was approximately $340 million (USD).
  May 17, 2012  
• Accuray appoints Richard Pettingill, LFACHE to board of directors  Accuray announced the appointment of Richard Pettingill, LFACHE as a member of the company's Board of Directors. Mr. Pettingill's most recently served as the President and CEO of Allina Health System, Minnesota's and western Wisconsin's largest healthcare organization.
  May 17, 2012  

   (next 10 articles)